Taylor & Francis
Taylor & Francis Group

RESEARCH PAPER

Nitrous anhydrase activity of carbonic anhydrase II: cysteine is required for nitric oxide (NO) dependent phosphorylation of VASP in human platelets

Dimitrios Tsikas[a] and Stepan Gambaryan[b]

[a]Institute of Toxicology, Core Unit Proteomics, Hannover Medical School, Hannover, Germany; [b]Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Petersburg, Russia

ABSTRACT

The carbonic anhydrase (CA) family does not only catalyse the reversible hydration of CO_2 to bicarbonate, but it also possesses esterase and phosphatase activity. Recently, bovine CA II and human CA II have been reported to convert inorganic nitrite ($O=N-O^-$) to nitric oxide (NO) and nitrous anhydride (N_2O_3). Given the ability of NO to mediate vasodilation and inhibit platelet aggregation, this CA II activity would represent a bioactivation of nitrite. There are contradictory reports in the literature and the physiological role of CA II nitrite bioactivation is still disputed. Here, we provide new experimental data in support of the nitrous anhydrase activity of CA II and the key role L-cysteine in the bioactivation of nitrite by CA II. Using washed human platelets and by measuring VASP phosphorylation we provide evidence that exogenous nitrite ($10\,\mu M$) is bioactivated to NO in a manner strongly depending on L-cysteine (100 and $200\,\mu M$). The process is not inhibitable by acetazolamide, a potent CA inhibitor. The contradictory results of recently published studies in this area are thoroughly discussed.

Introduction

The "inherent" catalytic activity of the carbonic anhydrase (CA, EC 4.2.1.1) family is the reversible hydration of CO_2 to bicarbonate (HCO_3^-) (R1) which is inhibited by several classes of drugs, among which sulphonamides (RSO_2NH_2) such as acetazolamide. In addition, CA isoforms are known for long time to possess esterase and phosphatase activity and to exert these activities by the same mechanism. Recently, bovine and human CA II have been reported to convert inorganic nitrite ($O=N-O^-$) to nitric oxide (NO)[1] and to nitrous anhydride (N_2O_3)[2,3]. While authentic NO can be directly detected, there is no analytical method to detect native N_2O_3 in biological samples thus far. N_2O_3 may exist in four very labile forms: one form is $ON-NO_2$ ($ON^\bullet + N^\bullet O_2 \leftrightarrow ON-NO_2$) without the nitrous anhydride structure N-O-N; the other three forms are isomeric $O=N-O-N=O$[4]. The results of our previous work[2,3] suggest that N_2O_3 has the structure $O=N-O-N=O$. This structure is used in the present work throughout.

The conversion of $O=N-O^-$ to NO is a redox reaction and implies the provision of one electron by the CA II. Yet, such a mechanism is difficult to reconcile for redox-inactive Zn^{2+}-containing CA II. A nitrous anhydrase activity of CA II seems more realistic, because such a reaction requires protons which can be easily provided by the enzyme (R2). Given the ability of NO to mediate vasodilation and inhibit platelet aggregation, and the potential of N_2O_3 to nitrosate different functionalities of biomolecules to form for instance S-nitrosothiols (RSNO; (R3)), N-nitrosoamines (RNHNO;

(R4)), the nitrous anhydrase CA II activity would represent a bioactivation of nitrite.

$$CO_2 + H_2O \leftrightarrow HCO_3^- + H^+ \tag{R1}$$

$$O=N-O^- + {}^-O-N=O + 2\,H^+ \leftrightarrow O=N-OH + HO-N=O$$
$$\leftrightarrow O=N-O-N=O + H_2O \tag{R2}$$

$$O=N-O-N=O + RSH \leftrightarrow O=N-O^- + RSNO + H^+ \tag{R3}$$

$$O=N-O-N=O + RNH_2 \leftrightarrow O=N-O^- + RNHNO + H^+ \tag{R4}$$

Nitrite and nitrate are metabolites of NO endogenously produced from L-arginine by the catalytic action of NO synthase (NOS). Exogenous nitrite and nitrate are also present in foods and drinking water and represent a considerable source of NO bioactivity via bacterial nitrate reductase activity in mouth and gut flora. Pharmacological nitrite, an NOS-independent source of NO, has protective effects in the cardiovascular system by decreasing blood pressure and inhibiting platelet activation[5]. Administration of nitrite has been reported to lower blood pressure and to inhibit platelet aggregation in vivo in humans and mice[6,7]. In contrast, nitrite added to washed human or mice platelets in vitro was found not to activate soluble guanylyl cyclase (sGC) and not to inhibit platelet activation[7,8]. We supposed that the different effects of nitrite in vivo and in washed platelets in vitro might be connected with the absence of extra-cellular L-cysteine in washed platelet preparations. In our experiments with washed human

platelets we tested this hypothesis and used L-cysteine at physiological concentrations.

The NO/sGC/protein kinase G (PKG) system is one of the most powerful mediators of platelet inhibition. Activation of PKG results in phosphorylation of multiple substrates involved in platelet inhibitory mechanisms. Vasodilator-stimulated phosphoprotein (VASP) is one of the well-established PKG substrates and is often used as a marker of the activation of this kinase[9]. In our experiments with washed human platelets, PKG activation was monitored by measuring VASP phosphorylation at Ser239 (P-VASP^{Ser239}) using phospho-specific antibodies. It is worth mentioning that human platelets contain CA I and CA II, but they do not contain NOS[10].

There are contradictory reports in the literature regarding the above mentioned newest CA II activities and even a disputation of a physiological role of CA II in the bioactivation of nitrite[11–14]. Here, we provide new experimental data in support of the nitrous anhydrase activity of CA II.

Materials and methods

Experiments with isolated CA II

NaNO$_2$ was obtained from Riedel-de-Haën (Seelze, Germany). 2,3,4,5,6-Pentafluorobenzyl bromide (PFB-Br), L-cysteine, bovine CA II and ^{15}N-labelled nitrite (Na^{15}NO$_2$; declared >98 atom % ^{15}N) were from Sigma-Aldrich (Steinheim, Germany). H$_2$^{18}O (declared isotopic purity >98 atom % ^{18}O) was purchased from Medical Isotopes (Pelham, New Hampshire, USA). The GC column Optima-17 (15 m × 0.25 mm i.d., 0.25-μm film thickness) and the conical glass vials were obtained from Macherey-Nagel (Düren, Germany). GC-MS analyses were performed on a ThermoElectron DSQ mass spectrometer coupled directly to a Thermo-Electron Focus gas chromatograph (GC) equipped with an autosampler AS 3000 (ThermoElectron, Dreieich, Germany). Quantification was performed by selected-ion monitoring (SIM) of ions with mass-to-charge (m/z) ratios of m/z 46 for ^{16}O=N-^{16}O$^-$, m/z 48 for ^{16}O=N-^{18}O$^-$ and ^{18}O=N-^{16}O$^-$, m/z 50 for ^{18}O=N-^{18}O$^-$, and m/z 47 for the internal standard (^{16}O=^{15}N-^{16}O$^-$, ^{15}NO$_2$$^-$). The dwell time was 50 ms for each ion.

The previously reported GC-MS method for nitrite and nitrate had been originally validated for 100-μL sample aliquots[15,16]. This method was adapted to 10-μL aliquots and validated for the CA microassay which involves the use of H$_2$^{18}O needed to prepare the aqueous buffer[3]. For highest derivatization yield of nitrite, the incubation time was 5 min. Under these conditions, nitrate cannot be quantified accurately[15]. We compared in parallel the methods using 100-μL (in quadruplicate) and 10-μL aliquots (in duplicate) of nitrite solutions in 100 mM Tris-HCl buffer, pH 7.4, in H$_2$^{16}O at added nitrite concentrations of 0, 2.5, and 5.0 μM. These concentrations were chosen because they were expected to be formed in experiments in H$_2$^{18}O-Tris buffer. The relative standard deviation values were 2.9% and 2.4%, 0.5% and 1.0%, and 3.1% and 4.3%, respectively. The regression equations obtained from linear regression analyses of measured nitrite (y) versus added nitrite (x) were $y = 0.752 + 0.645x$, $r^2 = 0.9945$ for the 100-μL samples and $y = 0.800 + 0.668x$, $r^2 = 0.9998$ for the 10-μL. The y-axis intercepts reveal nitrite concentrations in the Tris-HCl buffer of 0.75 μM and 0.80 μM, respectively. The slope values of the regression equations of 0.645 and 0.668 are very close indicating almost complete agreement (96.5%) between the procedures in the investigated concentration range.

Experiments with washed human platelets

Human washed platelets were prepared as reported previously[17] with small modifications. Blood was obtained from healthy volunteers, after they gave informed consent, according to our institutional guidelines and the Declaration of Helsinki. Studies using human platelets were approved by the Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences (IEPHB RAS) (Study No.3–03; 02.03.2019). Blood was collected into ACD solution (12 mM citric acid, 15 mM sodium citrate, 25 mM D-glucose, all final concentrations). Platelet rich plasma (PRP) was obtained by 5 min centrifugation at 330 × g; then collected PRP was centrifuged for 10 min at 430 × g, the pelleted platelets were washed in CGS buffer (120 mM sodium chloride, 12.9 mM trisodium citrate, 10 mM D-glucose, pH 6.5), and suspended in modified HEPES buffer (140 mM sodium chloride, 20 mM sodium bicarbonate, 5 mM potassium chloride, 1 mM magnesium chloride, 5 mM D-glucose, 10 mM HEPES, pH 7.4) to a final cell concentration of 3 × 10^8 platelets/mL. After 15 min rest in a 37 °C water bath, washed platelets (100 μL/tube) were used in the experiments. Platelets were incubated with 10 μM sodium nitrite, at 100 μM or 200 μM concentrations of L-cysteine. The NO donor, sodium nitroprusside (SNP, 1 μM) was used as a positive control. Acetazolamide (200 μM) was used for inhibition of CA activity, sGC activity was inhibited by 20 μM ODQ (both inhibitors were pre-incubated for 10 min). All chemicals in these experiments were obtained from Sigma-Aldrich (Steinheim, Germany).

For Western blot analysis, after incubation with the mentioned compounds, 100 μL of 3x Laemmli buffer were added to each tube, proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. The membranes were incubated with Phospho-VASP^{Ser239} Nanotools (Teningen, Germany) or actin (Cell Signalling, Frankfurt/am Main, Germany) primary antibodies overnight at 4 °C. For visualisation of the signal, goat anti-mouse (for Phospho-VASPSer239) or anti-rabbit (for actin) IgG conjugated with horseradish peroxidase were used as secondary antibodies followed by electrochemiluminescence detection (GE Healthcare). Blots were analysed densitometrically using NIH Image J software for uncalibrated optical density.

Experiments with purified S-[^{15}N]nitrosoalbumin

In order to investigate the effects of protein-bound Cu^{2+} and free L-cysteine on the formation of nitrite from a high-molecular-mass S-nitrosothiol we performed investigations with freshly prepared and purified S-[^{15}N]nitrosoalbumin without bound Cu^{2+} (i.e. S^{15}NALB) and with Cu^{2+} bound to S^{15}NALB (i.e. Cu^{2+}-S^{15}NALB), as well as with native albumin without bound Cu^{2+} (i.e. ALB) and with Cu^{2+} bound to albumin (i.e. Cu^{2+}-ALB) as described elsewhere[18–20]. For this, each 6-ml aliquots of freshly prepared plasma obtained by centrifugation (10 min, 800 × g, 4 °C) of EDTA-anticoagulated blood donated by a healthy young volunteer were used. These samples were used to prepare ALB and S^{15}NALB. Aliquots (2.5 ml) of the plasma samples were incubated for 10 min at room temperature with 1 mM CuSO$_4$ to prepare Cu^{2+}-ALB and Cu^{2+}-S^{15}NALB. All preparations were extensively purified using first Sephadex PD10 columns. Then eluates were extracted using 5-ml HiTrapBlue Sepharose affinity columns and washed with 100 ml of 67 mM potassium phosphate buffer, pH 7.0 (buffer A) in order to eliminate remaining free Cu^{2+}. Albumin species were eluted with 5 ml of 67 mM potassium phosphate buffer, pH 7.0, that contained 1.5 mM KCl (buffer B), the eluates were reduced to about 1-ml

using a stream of nitrogen gas and used subsequently without delay.

Each 50-μL aliquots of S^{15}NALB and Cu^{2+}-S^{15}NALB were incubated for 2 min at room temperature in buffer A in the absence (-Cys) or in the presence (+Cys) of L-cysteine at a final concentration of 100 μM. Each 50-μL aliquots of S^{15}NALB were incubated

with ALB or Cu^{2+}-ALB followed by their incubation in the absence (-Cys) or in the presence (+Cys) of L-cysteine at a final concentration of 100 μM as well. In order to quantify ^{15}N-nitrite in the samples, they were spiked with ^{14}N-nitrite as the internal standard at a final concentration of 10 μM and derivatized as described previously[15]. Each four 100-μL aliquots of all samples were treated with 10 μL of PFB-Br and 400 μL of acetone. Subsequently, the samples were incubated for 5 min at room temperature to generate the PFB derivatives of ^{15}N-nitrite and ^{14}N-nitrite with the latter serving as the internal standard. PFB derivatives were extracted with toluene (300 μL) and 1-μL aliquots thereof were analysed by GC-MS in the SIM mode: m/z 47 for ^{15}N-nitrite and m/z 46 for ^{14}N-nitrite. The concentration of ^{15}N-nitrite in the samples was calculated by multiplying the peak area ratio of m/z 47 to m/z 46 by 10 μM, which was the concentration of the internal standard in the samples.

Results

We demonstrated that bovine CA II (bCA II) catalyses the incorporation of ^{18}O into nitrite from H$_2$^{18}O used to prepare the pH-neutral buffered bCA II solution (Figure 1). Previously, we found that acetazolamide does not affect bCA II-catalyzed formation of NO from nitrite in the presence of exogenous L-cysteine at pH 7.4[3]. In that study we also found that acetazolamide itself did not affect the ^{18}O-incorporation from H$_2$^{18}O into nitrite in the absence of bCA II,[3] suggesting exclusive involvement of bCA II in this process. In the absence of L-cysteine, acetazolamide can modulate bCA II-catalyzed incorporation of ^{18}O from H$_2$^{18}O into nitrite in a concentration-dependent manner, leading to a higher ^{18}O-incorporation at 50 μM acetazolamide and to a lower ^{18}O-incorporation at 250 μM acetazolamide compared to no use of acetazolamide (Figure 1). The acetazolamide concentration of 50 μM is pharmacologically relevant in human plasma (mean C_{max}, 120 μM[21]). The acetazolamide concentration of 250 μM occurs in human urine upon ingestion of a single 250-mg acetazolamide tablet by

Figure 1. Concentrations of the nitrite species (A) ^{16}O$=$N-^{16}O$^-$, (B) ^{16}O$=$N-^{18}O$^-$ and ^{18}O$=$N-^{16}O$^-$, and (C) ^{18}O$=$N-^{18}O$^-$ upon incubation of sodium nitrite (100 μM) with bovine erythrocytic CA II (5 mg/mL, 172 μM) and acetazolamide (0, 25, 50, 100, 200 μM) for 10 min in 100 mM Tris buffer, pH 7.4, prepared in ^{18}O-water (>98% ^{18}O). The experiment was performed as described elsewhere[3]. Data are shown as mean with standard deviation from separate quadruplicate incubations. Statistical analysis was performed by one-way ANOVA and Mann-Whitney test.

Figure 2. Concentrations of the nitrite species (left panel) ^{16}O$=$N-^{16}O$^-$, (middle panel) ^{16}O$=$N-^{18}O$^-$ and ^{18}O$=$N-^{16}O$^-$, and (right panel) ^{18}O$=$N-^{18}O$^-$ upon incubation of sodium nitrite (100 μM) with bovine erythrocytic CA II (5 mg/mL, 172 μM) in 100 mM Tris buffer, pH 7.4, prepared in ^{18}O-water (>98% ^{18}O) in the absence of L-cysteine (-Cys) or in the presence of L-cysteine (+Cys) at 100 μM. The experiment was performed as described elsewhere[3]. Data are shown as mean with standard deviation from four independent incubations. Statistical analysis was performed by one-way ANOVA and Mann-Whitney test.

Figure 3. Cysteine is required for the bioactivation of nitrite to NO in human platelets. Washed human platelets (3×10^8/mL, 100 μL) were incubated with indicated compounds. The concentration of $NaNO_2$ was 10 μM where added. L-Cysteine (Cys) was added at final concentrations of 100 μM or 200 μM. The incubation time was 5 min. Sodium nitroprusside (SNP) was used at 1 μM (1 min) and served as positive control. Some samples were pre-incubated for 10 min with the CA inhibitor acetazolamide (ACZ) at 200 μM, or with the sGC inhibitor ODQ at 20 μM; then $NaNO_2$ and Cys were added and the samples were incubated for 10 min. All samples were processed for Western blot analysis of VASP^{Ser239} phosphorylation, with actin blots serving as loading control. Blots were scanned and analysed densitometrically using NIH Image J software for uncalibrated optical density (graph). Results are presented as mean with standard deviation from quadruplicate analyses. Asterisk (*) indicate p values < 0.05 compared to control. Statistical analysis was performed by one-way ANOVA and Student's t-test.

healthy subjects[22]. The results of Figure 1 suggest that acetazolamide may modulate the nitrous anhydrase activity of bCA II in a non-linear concentration-dependent manner. A similar phenomenon was observed for the esterase activity of human CA II (hCA II) towards carbohydrate-based sulfamate inhibitors[23].

By using this method we found that bovine and human erythrocytic CA II catalyses the incorporation of ^{18}O atoms from $H_2^{18}O$ used to prepare the 100 mM Tris-HCl buffer, pH 7.4, into nitrite, suggesting intermediate formation of nitrous anhydride and its subsequent hydrolysis to form singly and doubly ^{18}O-labelled nitrite with m/z 48 and m/z 50, respectively[3]. The presence of exogenous L-cysteine at a concentration of 100 μM was found to potentiate the nitrous anhydrase activity (incorporation of ^{18}O)[3]. In present study we also measured the concentration of remaining (unlabeled) nitrite, i.e. $^{16}O_2$-nitrite (m/z 46). The results of these investigations are illustrated in Figure 2. To our surprise, we observed a strong decrease in the concentration of $^{16}O_2$-nitrite (m/z 46), i.e. from 56.9 ± 3.35 μM without L-cysteine to 3.85 ± 1.28 μM in the presence of 100 μM L-cysteine ($P = 0.029$). bCA II-mediated consumption of nitrite was observed in the absence of external L-cysteine, albeit to a smaller extent (e.g. 70.3 ± 4.8 μM vs. 54.2 ± 11.4 μM; by 23%). In the absence of bCA II no such decrease or formation of m/z 48 and m/z 50 in the 100 mM Tris-HCl buffer, pH 7.4, was observed. These findings have not been reported previously and suggest a considerable consumption of nitrite in a manner dependent on bCA II and L-cysteine. Possible reactions could involve nitration of certain CA II amino acid residues including Cys^{205}, the single L-cysteine residue

of CA II, and various L-tyrosine residues (8 Tyr residues in CA II[24]). As tris(hydroxymethyl)aminomethane was used at 100 mM to prepare the Tris buffer, we cannot exclude a reaction of nitrous anhydride with tris(hydroxymethyl)aminomethane (pK_a, 7.81) to form tris(hydroxymethyl)-N-nitroso-aminomethane which would simulate nitrite consumption. In the absence of L-cysteine the molarity of Tris buffer (10 − 100 mM) had not effect of nitrite consumption[3]. In this context it is notable that tris(hydroxymethyl)aminomethane can also react with p-nitrophenylacetate[25] which is commonly used to measure the esterase activity of CA.

Incubation of washed human platelets with 10 μM sodium nitrite or 100 μM L-cysteine alone did not result in an increase of the P-VASP/actin ratio as compared to control (Figure 3). The intra-platelet P-VASP/actin ratio increased almost 6-fold upon of co-incubation of platelets with 10 μM sodium nitrite and 200 μM L-cysteine (Figure 3). This increase was very similar to that observed by incubating the washed human platelets with 1 μM sodium nitroprusside (SNP, $Na_2[Fe(CN)_5NO]$). The P-VASP/actin ratio was dependent upon the added L-cysteine concentration. At 100 μM acetazolamide, the P-VASP/actin ratio observed from 10 μM sodium nitrite/100 μM L-cysteine was almost the same as in the absence of acetazolamide, apparently suggesting no involvement of platelet CA. In contrast, pre-incubation of washed human platelets with ODQ, an inhibitor of sGC[26], inhibited the phosphorylation of VASP, suggesting conversion of sodium nitrite to NO.

Human serum albumin (ALB) has a single cysteine moiety that does not form intra-molecular disulphide bridges. This cysteine moiety (Cys34) is accessible to modifications including S-nitrosation by nitrous anhydride and alkyl nitrites to form S-nitrosoalbumin (SNALB). SNALB itself is not an NO donor, but can release NO indirectly by means of free L-cysteine and intermediate formation of S-nitrosocysteine (CysSNO) via S-transnitros(yl)ation reactions.[18–20] In the present study we investigated whether Cu^{2+} ions bound to albumin (Cu-ALB) and S^{15}NALB (Cu-S^{15}NALB) may modulate the L-cysteine-dependent release of NO from SNALB in buffer of neutral pH. Because nitrite (i.e. ^{14}N-nitrite) is abundantly present as a contamination we used commercially available ^{15}N-nitrite, i.e. the nitrite analog labelled with the stable isotope ^{15}N, of which the natural abundance is 0.36%. The results of this experiment are shown in Figure 4.

Addition of L-cysteine at 100 μM to virtually Cu^{2+}-free S^{15}NALB alone or in the presence of Cu^{2+}-free ALB in potassium phosphate buffer did not result in elevated formation of ^{15}N-nitrite. In contrast, addition of L-cysteine at 100 μM to Cu^{2+}-bound S^{15}NALB (Cu-S^{15}NALB) alone or in the presence of Cu^{2+}-containing ALB (Cu-ALB) did result in elevated formation of ^{15}N-nitrite by 37% and 34%, respectively. These results indicate that free L-cysteine interacts with Cu-S^{15}NALB and S^{15}NALB − Cu-ALB. However, the results of Figure 4 do not exclude the possibility that the incubation of S^{15}NALB with Cu-ALB have resulted in formation of Cu-S^{15}NALB prior to the addition of L-cysteine.

Discussion

In the sections that follow below, we discuss the results of the present study and previous studies from our groups in the context of the results reported by other groups with respect to CA II functions as nitrous anhydrase or nitrite reductase. The discussion addresses mechanistic aspects and results from in vitro and in vivo studies.

Figure 4. L-Cysteine, copper ions bound to albumin (Cu-ALB) and S-[^{15}N]nitrosoalbumin (Cu-S^{15}NALB) are required for the formation of ^{15}N-nitrite from S^{15}NALB. The initial concentrations were 13 μM for S^{15}NALB and 15 μM for Cu-S^{15}NALB. The concentration of free L-cysteine added to the samples (+Cys) was 100 μM. The concentration of free L-cysteine in the samples non-spiked with L-cysteine (-Cys) is unknown. The protein concentration in ALB, Cu-ALB, S^{15}NALB and Cu-S^{15}NALB was about 300 μM.

Mechanistic aspects: CA II as nitrous anhydrase and nitrite reductase

Pickerodt et al. 2019[13] investigated the effects of inhaled sodium nitrite (iNaNO$_2$) alone and in combination with intravenously administered acetazolamide (ivACZ), a strong inhibitor of hCA II (IC$_{50}$, 12 nM[26]), in pigs under hyperoxic and hypoxic conditions. Based on missing differences of single iNaNO$_2$ and combined administration of iNaNO$_2$ and ivACZ with respect to various parameters, the authors concluded that CA is not a relevant nitrite reductase or nitrous anhydrase in the lung[13]. We agree with these authors that there is no convincing structure within the active site of the Zn^{2+}-containing hCA II (i.e. Zn-hCA II), notably including the central redox-inactive Zn^{2+}, or elsewhere in this protein capable of supporting one-electron reduction of nitrite (N oxidation state, +3) to form NO (N oxidation state, +2): ON^{III}O$^-$ + e$^-$ + H$_2$O → N^{II}O + 2 OH$^-$. Hence, Zn-hCA II does not possess a nitrite reductase activity in contrast to the first proposal by Aamand et al. 2009[1] and the later study by Nielsen & Fago[27] based on the measurement of NO in their studies. Our groups found by a NO-selective electrode that Zn^{2+}-containing bovine CA II (Zn-bCA II) and Zn-hCA II do not generate NO from nitrite in aqueous buffer of neutral pH in the absence or in the presence of acetazolamide or dorzolamide[2,3]. Aamand et al. 2009[1] and Nielsen & Fago 2015[27] reported that Zn-CA II-induced generation of NO from nitrite, which was even increased by the CA inhibitor dorzolamide stronger at pH 5.9 compared to pH 7.3. A possible explanation for these findings could be NO formation from the chemical reaction of nitrite with the amine (NH$_2$) group of the sulphonamide functionality of dorzolamide at pH 5.9. Such reactions have been reported for many sulphonamides of which the amine group is quite acidic and easily nitrosable by nitrous acid (ONOH) and N$_2$O$_3$ to finally decompose to NO[28]. An alternative explanation could be that the Zn-CA II preparation used in that study contained contaminating Cu^{2+} (see below). On the other hand, we do not agree with Pickerodt et al. 2019[13] that CA II does not exert nitrous anhydrase activity to produce N$_2$O$_3$ from the labile intermediate nitrous acid: ONO$^-$ + ONO$^-$ + 2 H$^+$ → 2 [ONOH] → N$_2$O$_3$ + H$_2$O. The conversion of ONO$^-$ to N$_2$O$_3$ is not a redox reaction and does not require any electrons, but solely protons that can be provided by CA II even in the absence of CO$_2$/HCO$_3^-$ (R1). The results by Aamand et al.[1] are also supportive of a nitrous anhydrase activity of bCA II leading to the gaseous thus far undetectable N$_2$O$_3$ which may in part decompose to NO[4], thus producing signals when measured by a NO-electrode or by chemiluminescence.

Andring et al.[11] reported that Zn-CA II, a cytosolic CA isozyme, does not exhibit nitrate reductase or nitrous anhydrase activity. We agree that Zn-CA II is not a nitrate reductase, but we disagree that Zn-CA II is not a nitrous anhydrase. Our groups[2,3] found by liquid chromatography-tandem mass spectrometry (LC-MS/MS) that bCA II and hCA II generated in the presence of glutathione (GSH) S-nitrosoglutathione (GSNO); we also found that in the presence of exogenous L-cysteine, bCA II and hCA II mediated NO formation as measured by a NO-sensitive electrode most likely via intermediate formation of S-nitrosocysteine (CysSNO), a potent NO donor. GSNO and CysSNO exert both cGMP-dependent (via NO release) and cGMP-independent (via S-transnitrosylation) biological activities, including vasodilation and inhibition of platelet aggregation.[29–31] The results reported in the present study using washed human platelets, nitrite and L-cysteine are in support of intra-platelet Zn-CA II-mediated conversion of nitrite to NO via intermediate formation of CysSNO from N$_2$O$_3$ and L-cysteine, but not via reduction of nitrite to NO. We have demonstrated by mass spectrometry-based proteomic studies that CA II is physiologically present in platelets of healthy humans (35,000 copies/platelet).[10]

Our studies suggest that upon hCA II-induced conversion of nitrite to N$_2$O$_3$, this anhydride has the potential to develop NO-related bioactivity by subsequent redox-independent reactions. One mechanism may involve S-nitrosylation by N$_2$O$_3$ of the Cys^{205} moiety of Zn-hCA II to form hCA II-Cys^{205}-S-N=O (R5a). Cys^{205} is in close proximity to the active site of Zn-hCA II. N$_2$O$_3$ could also O-nitrosylate the acidic aromatic hydroxyl (OH) group of the Tyr^7 residue of Zn-hCA II to form Zn-hCA II-Tyr^7-O-N=O (R6a). Tyr^7 is in close proximity to His^{64} in the active site of Zn-hCA II as well. Although Tyr^7 is not required for efficient hydratase and esterase

activity, it is considered important for the stabilisation of the protein[32,33]. Subsequent reactions of Zn-hCA II-Cys^{205}-S-N$=$O and Zn-hCA II-Tyr^7-O-N$=$O with cytosolic GSH (R5b, R5c, R6b, R6c) would yield GSNO. In addition, N_2O_3 generated by the cytosolic Zn-hCA II could react with other cytosolic thiols including GSH and L-cysteine (R7, R8) and membranous thiols[34]. The reaction of GSNO with L-cysteine (CysSH) would form CysSNO (R9). CysSNO can be actively transported through cell membranes and donate NO[34].

Nitrite reacts both with water and CO_2, and these reactions can be modulated by Zn-hCA II[35]. The pK_a value of H_2CO_3 during its formation in aqueous solution is 3.5[36], i.e. it is much lower than the generally assumed value of 6.4. Zn-hCA II-dependent N_2O_3 formation from nitrite and CO_2 could occur via nitritocarbonate/nitritocarbonic acid (O$=$N-O-COO$^-$/O$=$N-O-COOH) across the proton transfer shuttle (R10).

$$hCA\ II-Cys^{205}-SH + O=N-O-N=O \rightarrow hCA\ II-Cys-S^{205}-N$$
$$= O + O = N-O^- + H^+$$
$$(R5a)$$

$$hCA\ II-Cys^{205}-S-N=O + G-S-H$$
$$\leftrightarrow hCA\ II-Cys^{205}-SH + G-S-N=O \quad (R5b)$$

$$hCA\ II-Cys^{205}-S-N=O + Cys-S-H$$
$$\leftrightarrow hCA\ II-Cys^{205}-SH + Cys-S-N=O$$
$$(R5c)$$

$$hCA\ II-Tyr^7-OH + O=N-O-N=O \rightarrow hCA\ II-Tyr^7-O-N$$
$$= O + O = N-O^- + H^+$$
$$(R6a)$$

$$hCA\ II-Tyr^7-O-N=O + G-S-H \rightarrow hCA\ II-Tyr^7-OH + G-S-N$$
$$= O$$
$$(R6b)$$

$$hCA\ II-Tyr^7-O-N=O + Cys-S-H$$
$$\rightarrow hCA\ II-Tyr^7-OH + Cys-S-N=O \quad (R6c)$$

$$O=N-O-N=O + G-S-H \rightarrow O=N-O- + G-S-N=O \quad (R7)$$

$$O=N-O-N=O + Cys-S-H \rightarrow O=N-O- + Cys-S-N=O$$
$$(R8)$$

$$G-S-N=O + Cys-S-H \leftrightarrow G-S-H + Cys-S-N=O \quad (R9)$$

$$O=N-O-COOH + O=N-O^- + \rightarrow O=N-O-N=O + {}^-OCOOH$$
$$(R10)$$

Potential nitrite-dependent physiological and pharmacological roles of carbonic anhydrase

Besides mechanistic aspects, other important issues should also be considered in the context of nitrite-dependent physiological and pharmacological roles of Zn-hCA and are discussed below.

In the study by Pickerodt et al.[13], sodium nitrite (NaNO$_2$, 450 mg, 6.5 mmol) was inhaled by juvenile male 24-kg weighing pigs. This corresponds to a dose of 18.8 mg/kg body weight and is about 16 times higher than the reported maximum tolerated dose of iNaNO$_2$ in healthy humans[37]. After 1 h of hypoxia, arterial blood nitrite concentration increased 35-fold after iNaNO$_2$ alone and even 48-fold after co-administration with ivACZ[13]. After 2 h of hypoxia, arterial blood nitrite concentration was only 8 μM in both cases, suggesting a short elimination half-life of nitrite. Mean arterial blood pressure decreased almost equally with iNaNO$_2$ alone (79 to 60 mmHg) and in co-administration of acetazolamide (79 to 56 mmHg) after 1 h of hypoxia[13]. The average fractional excretion of NO (FENO) increased from 6 ppb at baseline to 46 ppb at 1 h, and fall to 27 ppb at 2 h, and to 20 ppb at 3 h upon iNaNO$_2$ alone; the corresponding FENO values for iNaNO$_2$+ivACZ were 6 ppb, 22 ppb, 13 ppb, and 11 ppb, i.e. constantly (almost by 50%) lower[13]. In that study, considerable differences between iNaNO$_2$ and iNaNO$_2$+ivACZ were also found for the respiratory rate. Despite considerable differences in some pharmacodynamic parameters, for instance 1) the lower FENO values (by 24, 14 and 9 ppb after 1 h, 2 h and 3 h of hypoxia) and 2) the mean pulmonary arterial pressure (MPAP) of the combination of iNaNO$_2$+ivACZ compared to iNaNO$_2$ alone (by 9 and 8 mmHg after 2 h and 3 h of hypoxia), the authors concluded that CA is not relevant to the bioactivation of nitrite[13]. We think that these observations may suggest that at the very high dose of iNaNO$_2$ used in the study[13], iNaNO$_2$ may have attenuated/inhibited the nitrous anhydrase CA activity in the lungs. Acetazolamide has been demonstrated to increase the excretion of endogenous and exogenous nitrite and to a lower degree of nitrate in humans[16,22,38,39]. Although nitrite, nitrate and bicarbonate had not been measured in the urine, Pickerodt et al.[13] concluded, solely on the basis of the plasma nitrite concentration course, which in fact differed between the groups, that acetazolamide did not alter renal function including CA-dependent reabsorption of nitrite and nitrate. As far as we are informed, plasma nitrite concentrations of the order of 35 μM and 48 μM as found at 1st h of hypoxia[13] have not been reported until the present day. At such high concentrations the activity of many enzymes including erythrocytic catalase are likely to be inhibited to a considerable degree thus increasing oxidative stress and methemoglobinemia[40].

In healthy subjects (mean weight, 60.7 kg), iNaNO$_2$ (75 mg, 1.09 mmol) for 10 min resulted in a 20-fold increase of the mean blood nitrite concentration (from 0.2 μM to 4 μM) which decreased with an elimination half-life of 0.6 h[41]. The average FENO increased from 10 ppb at baseline to 40 ppb and fell to the baseline levels 10 min after NaNO$_2$ inhalation[41]. No significant changes of systolic and diastolic pressure were observed in the human study, in which the iNaNO$_2$ dose was 1.2 mg/kg body weight, i.e. much lower compared to the dose of 18.8 mg/kg body weight used in the study by Pickerodt et al.[13]. The results of the studies by Pickerodt et al.[13] and Sirirat et al.[41] indicate a very rapid elimination of iNaNO$_2$ in accordance with an elimination half-life of about 0.5 h in humans[37]. The nitrite bioavailability of iNaNO$_2$ in healthy subjects was reported to be 18%[41]. Unfortunately, neither nitrite nor nitrate excretion rates in the urine were reported in the studies by Pickerodt et al.[13] and Sirirat et al.[41]. Such data would have allowed evaluating the expected drastically elevated excretion of nitrite due to inhibition of renal CA activity by acetazolamide in the animal study, as observed by us in humans at a pharmacological dose of acetazolamide[16,22,39].

In 16 healthy young subjects (mean age, 23 years) who received intravenous infusion of NaNO$_2$ (approximate dose, 0.48 mg/kg body weight) for 2 h after a 4-days pharmacological treatment period with placebo (only NaNO$_2$, no drug) as control, allopurinol to inhibit xanthine oxidoreductase (XOR) activity, enalapril to inhibit angiotensin converting enzyme (ACE) activity, or acetazolamide (250 mg thrice a day) to inhibit CA activity, consistent results with respect to many parameters were obtained with all medications[6]. The authors concluded that the effects observed in their study, including the decrease of mean arterial pressure (−1.88 mmHg by placebo; −1.84 mmHg by allopurinol; −2.07 mmHg by enalapril; −2.32 mmHg by acetazolamide) suggest that XOR, ACE and CA are not essential for nitrite bioactivation to NO[6]. Yet, this conclusion is not convincing for the following reasons: the NaNO$_2$ dose was low and the infusion period was

relatively long when compared with the short elimination half-life of nitrite of 0.6 h; also the greatest effect of acetazolamide on nitrite excretion is quite rapidly exerted[16,22,39].

A sophisticated animal study was performed by Wang et al.[14]. In CA II[+/+], CA II± and CA II[-/-] mice (26 − 32 g body weight), infusion of NaNO$_2$ (30, 50, 100, 500, 2500 nmol over 5 min corresponding to doses of up to 3.8 mg nitrite/kg body weight) lowered mean arterial blood pressure equally from about 70 mmHg down to 40 mmHg in CA II[+/+], CA II± and CA II[-/-], suggesting a mechanism independent of CA II[14]. Unfortunately, the authors did not report on the possible formation of S-nitrosothiols, which could have been an indication of hCA II involvement. It is worth mentioning that increase in plasma S-nitrosothiol concentration was observed upon iNaNO$_2$ for 10 min in doses of 0.06 to 2.2 mg NaNO$_2$/kg body weight in healthy subjects[37]. Our group provided unequivocal evidence of the formation of ^{15}N-labelled S-nitroso-glutathione (GS[15]NO) from ^{15}N-labelled nitrite and GSH by means of a commercially available recombinant human erythrocytic CA II (heCA II) in Tris buffer at pH 7.4 in the absence of externally added bicarbonate[2]. In washed human platelets, the activity of sGC upon incubation with 100 μM nitrite, 20 mM bicarbonate and bovine erythrocytic CA II was comparable with that observed with 1 μM S-nitrosocysteine (CysSNO), one of the strongest endogenous inhibitors of platelet aggregation[29]. In the present study, comparable effects were obtained with 10 μM nitrite and 100 μM L-cysteine. This may suggest that 10 μM nitrite/100 μM L-cysteine is about 10 less active that SNP regarding NO formation.

Although CAs are investigated for several decades by many groups from various perspectives including biology and pharmacology, the CA family conceals many secrets and surprises[23] that remain to be revealed. While there is solid evidence of the participation of renal CA II and CA IV in the reabsorption of endogenous and exogenous nitrite[16,39], the mechanisms underlying the bioactivation by CA II of nitrite to species such as N$_2$O$_3$ with the potential of developing NO-related activity are still elusive and warrant further research. In vitro, haemoglobin species, XOR, ACE and CA have been shown to bioactivate nitrite under some specific conditions which included hypoxia and slightly acidic pH. The use of inhibitors of hCA II, XOR and ACE in studies on the bioactivation of nitrite is problematic for several reasons. The nitrous anhydrase activity of CA II and its importance in the bioactivation of inorganic nitrite to NO and S-nitrosothiols warrants further characterisation. Pharmacological acetazolamide exerts dilatory effects by not yet well-understood mechanisms, presumably in part independent of NO/cGMP[23]. The underlying mechanisms need elucidation before acetazolamide and other CA inhibitors can be used to test the involvement of hCA II in the bioactivation of nitrite. In this context the possibility should be considered that the use of hCA II inhibitors may result in loss of nitrite due to elevated renal excretion in the urine thus counteracting its bioactivation in other tissues. Measurement of urinary nitrite excretion in in vivo studies investigating the bioactivation of inorganic nitrite by CAs is mandatory. Lack of elevated urinary nitrite excretion and of other measures in the CA II[-/-] mice[14] could be due to alterations of other CA isozymes and proteins such as renin and aquaporin[42–44].

Are Zn- and copper-containing carbonic anhydrases (CuZnCA) responsible for contradictory results regarding nitrite bioactivation?

Cu^{2+} ions were found to bind to Zn^{2+}-CA II isolated from human erythrocytes at a site other than the active site and to inhibit the exchange of water from the enzyme without affecting the equilibrium rate of hydration of CO$_2$ by Tu et al. [45] almost four decades ago. This observation may suggest that classical CA inhibitors such as acetazolamide may inhibit the carbonic anhydrase activity of CA by tightly binding to CA II-bound Zn^{2+}, but not to the second Cu^{2+}-binding site. This may be an explanation for our previous[2,3] and present (Figure 3) observations that neither acetazolamide nor dorzolamide inhibited the nitrous anhydrase activity of isolated bovine and human CA II.

The results of the present study observed with Cu-S[15]NALB and Cu-ALB suggest that L-cysteine is required for the bioactivation of the S-nitroso group of S-nitrosoalbumin (SNALB) either containing firmly bound Cu^{2+} or in the presence of non-S-nitrosylated but Cu^{2+} bound to albumin (Cu-ALB). It is likely that similar effects and mechanisms may also occur in ZnCu-CA II and CuCu-CA II. Yet this remains to be demonstrated by experiments analogous to those performed with Cu-S[15]NALB and Cu-ALB in the present study.

Zn-hCA II that additionally contains Cu^{2+} arising from contaminations or from Cu^{2+}-containing proteins/enzymes such as ceruloplasmin could act as a nitrite reductase. The dependence of the nitrous anhydrase/nitrite reductase activity of CA II upon L-cysteine would be compatible with these particular activities. Reaction of L-cysteine with N$_2$O$_3$ in the bulk would form CysSNO (R8) of which the S-nitroso group is reduced to NO by Cu^{1+} ions (R11) formed from the reaction of Cu^{2+} with L-cysteine (R12). The so-called copper carbonic anhydrase has been in the past[46,47] and is currently[48–51] of particular interest not least because of its potential nitrite reductase activity. Reactions analogous to (R11) and (R12) could be formulated for zinc/copper human carbonic anhydrase II ([Zn^{2+}/Cu^{2+}]hCA II) (R13, R14). Based on a crystallographic study, it has been proposed that [Cu^{2+}/Cu^{2+}]hCA II is a nitrite reductase[50,51], but no experimental evidence has been reported that nitrite is indeed reduced to NO by [Cu^{2+}/Cu^{2+}]hCA II or [Zn^{2+}/Cu^{2+}]hCA II) (R15)[52]. It is also unknown whether L-cysteine or ascorbic acid is required as reductants for Cu^{2+} bound to hCA II.

$$Cys-S-N=O + Cu^{1+} \rightarrow Cys-S^- + N^\bullet = O + Cu^{2+} \quad (R11)$$

$$Cu^{2+} + Cys-S-H \rightarrow Cu^{1+} + Cys-S^\bullet + H^+ \quad (R12)$$

$$\left([Zn^{2+}/Cu^{1+}]\right)hCA\ II-Cys^{205}-S-N=O$$
$$\rightarrow \left([Zn^{2+}/Cu^{2+}]\right)hCA\ II-Cys^{205}-S^- + N^\bullet = O \quad (R13)$$

$$\left([Zn^{2+}/Cu^{2+}]\right)hCA\ II-Cys^{205}-S-H + Cys-S-H$$
$$\rightarrow \left([Zn^{2+}/Cu^{1+}]\right)hCA\ II-Cys^{205}-S^- + Cys-S^\bullet + H^+ \quad (R14)$$

$$\left([Zn^{2+}/Cu^{1+}]\right)hCA\ II-Cys^{205}-S-H + O=N-O^-$$
$$\rightarrow \left([Zn^{2+}/Cu^{2+}]\right)hCA\ II-Cys^{205}-S-H + N^\bullet = O \quad (R15)$$

Human serum albumin (HSA) contains two specific Cu^{2+} binding sites, the N-terminal site (NTS) and the multimetal binding site (MBS). The NTS binds Cu^{2+} ions much more strongly than the MBS, and it is therefore considered to be the only HSA site ever occupied by Cu^{2+} ions in blood serum. In vitro, the incorporation of Cu^{2+} into HSA is fast. The affinity of Cu^{2+} to the NTS of HSA is 1 pM[53]. Under physiological conditions only about 1% of HSA molecules are estimated to carry a Cu^{2+} ion. About 25% of HSA molecules derived from human blood have their N-terminal dipeptide clipped and do not possess an NTS. The NTS is composed of the first three amino acid residues of the HSA sequence: Asp-Ala-His. In our study we did not determine the concentrations of Cu-S[15]NALB and Cu-ALB. We consider that they correspond to the measured protein concentrations. Externally added Cu^{2+} ions are likely to be bound on the NTS of our synthesised and purified

Cu-S[15]NALB and Cu-ALB preparations, with no appreciable mutual hindrance and fully accessibility for L-cysteine. It is possible that Cu^{2+}-containing CA may act as a nitrite reductase analogous to Cu^{2+}-bound HSA, but this remains to be demonstrated in forthcoming experiments.

Conclusions and perspectives

Several endogenous and exogenous sources contribute to inorganic nitrite. Do bovine and human carbonic anhydrase isoforms, notably CA II, possess nitrous anhydrase activity or nitrite reductase activity like bacterial nitrite reductases or possibly both? These questions are currently in the focus of scientific research due to the potential bioactivation of inorganic nitrite to nitric oxide (NO) and nitrous anhydride (N_2O_3). NO is a potent vasodilatator and inhibitor of platelet aggregation, which are considered to be beneficial in certain cardiovascular diseases. N_2O_3 can nitrosate numerous biomolecules thus potentially contributing to health via *S*-nitrosation and subsequent NO release, or to disease such as cancer via *N*-nitrosation. Existing results from *in vitro* and in vivo experiments in animals and humans including the effects of established and novel carbonic anhydrase inhibitors, including those for treatment of hypoxic tumours,[54] are contradictory, often misinterpreted (discussed in References[52,55]), and difficult to reconcile. The lack of an inhibitory effect of acetazolamide on nitrous anhydrase/nitrite reductase activity of carbonic anhydrase is often interpreted as a CA-independent effect. The potentiation of the effects of CA on nitrite by L-cysteine seen in human washed platelets in our study is compatible with nitrous anhydrase activity of intra-platelet CA accompanied by subsequent NO release. This can be concluded because measuring of VASP phosphorylation is considered to reflect platelet-derived NO[56]. This effect may simulate "nitrite reductase" activity of CA. Yet, due to the ability of CA to bind Cu^{2+} on a site distinctly different from the Zn^{2+} site, further investigations using sophisticated analytical approaches, such as GC-MS in combination with stable-isotope labelled water and nitrite[57], and proteomics, are required to reveal hidden biochemical properties of CA II and other CA-isoforms beyond their inherent carbonic anhydrase activity (R1). *S*-Glutathionylation of CA VII was found not to be associated with loss of catalytic activity and affinity for sulphonamide inhibitors[58]. Such investigations are required for Zn-hCA II regarding the involvement of Cys[205] in the nitrous anhydrase activity, and for Cu-hCA II regarding the involvement of Cys[205] in its proposed nitrite reductase activity.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

ORCID

Dimitrios Tsikas 🔟 http://orcid.org/0000-0001-6320-0956
Stepan Gambaryan 🔟 http://orcid.org/0000-0002-1470-0791

References

1. Aamand R, Dalsgaard T, Jensen FB, et al. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol Heart Circ Physiol 2009;297:H2068–74.
2. Hanff E, Böhmer A, Zinke M, et al. Carbonic anhydrases are producers of *S*-nitrosothiols from inorganic nitrite and modulators of soluble guanylyl cyclase in human platelets. Amino Acids 2016;48:1695–706.
3. Zinke M, Hanff E, Böhmer A, et al. Discovery and microassay of a nitrite-dependent carbonic anhydrase activity by stable-isotope dilution gas chromatography-mass spectrometry. Amino Acids 2016;48:245–55.
4. Nedospasov AA. Is N_2O_3 the main nitrosating intermediate in aerated nitric oxide (NO) solutions in vivo? If so, where, when, and which one? J Biochem Mol Toxicol 2002;16:109–20.
5. Liu Y, Croft KD, Hodgson JM, et al. Mechanisms of the protective effects of nitrate and nitrite in cardiovascular and metabolic diseases. Nitric Oxide 2020;96:35–43.
6. Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 2008;51:784–90.
7. Apostoli GL, Solomon A, Smallwood MJ, et al. Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. J Thromb Haemost 2014;12:1880–9.
8. Gambaryan S, Subramanian H, Kehrer L, et al. Erythrocytes do not activate purified and platelet soluble guanylate cyclases even in conditions favourable for NO synthesis. Cell Commun Signal 2016;14:16
9. Makhoul S, Walter E, Pagel O, et al. Effects of the NO/soluble guanylate cyclase/cGMP system on the functions of human platelets. Nitric Oxide 2018;76:71–80.
10. Burkhart JM, Vaudel M, Gambaryan S, et al. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012;120:e73–e82.
11. Andring JT, Lomelino CL, Tu C, et al. Carbonic anhydrase II does not exhibit nitrite reductase or nitrous anhydrase activity. Free Radic Biol Med 2018;117:1–5.
12. Rosenbaek JB, Pedersen EB, Bech JN. The effect of sodium nitrite infusion on renal function, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamide in healthy subjects: a randomized, double-blinded, placebo-controlled, crossover study. BMC Nephrol 2018;19:244.
13. Pickerodt PA, Kronfeldt S, Russ M, et al. Carbonic anhydrase is not a relevant nitrite reductase or nitrous anhydrase in the lung. J Physiol 2019;597:1045–58.
14. Wang L, Sparacino-Watkins CE, Wang J, et al. Carbonic anhydrase II does not regulate nitrite-dependent nitric oxide formation and vasodilation. Br J Pharmacol 2020;177:898–911.
15. Tsikas D. Simultaneous derivatization and quantification of the nitric oxide metabolites nitrite and nitrate in biological fluids by gas chromatography/mass spectrometry. Anal Chem 2000;72:4064–72.
16. Tsikas D, Schwarz A, Stichtenoth DO. Simultaneous measurement of [15N]nitrate and [15N]nitrite enrichment and concentration in urine by gas chromatography mass spectrometry as pentafluorobenzyl derivatives. Anal Chem 2010;82:2585–7.

17. Gambaryan S, Kobsar A, Rukoyatkina N, et al. Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex. J Biol Chem 2010;285:18352–63.

18. Tsikas D, Sandmann J, Rossa S, et al. Measurement of S-nitrosoalbumin by gas chromatography-mass spectrometry. I. Preparation, purification, isolation, characterization and metabolism of S-[15N]nitrosoalbumin in human blood in vitro. J Chromatogr B Biomed Sci Appl 1999;726:1–12.

19. Tsikas D, Sandmann J, Gutzki FM, et al. Measurement of S-nitrosoalbumin by gas chromatography-mass spectrometry. II. Quantitative determination of S-nitrosoalbumin in human plasma using S-[15N]nitrosoalbumin as internal standard. J Chromatogr B Biomed Sci Appl 1999;726:13–24.

20. Tsikas D, Sandmann J, Frölich JC. Measurement of S-nitrosoalbumin by gas chromatography–mass spectrometry. III. Quantitative determination in human plasma after specific conversion of the S-nitroso group to nitrite by cysteine and Cu^{2+} via intermediate formation of S-nitrosocysteine and nitric oxide. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772:335–46.

21. Zarghi A, Shafaati A. Rapid determination of acetazolamide in human plasma. J Pharm Biomed Anal 2002;28:169–72.

22. Begou O, Drabert K, Theodoridis G, Tsikas D. GC-NICI-MS analysis of acetazolamide and other sulfonamide (R-SO2-NH2) drugs as pentafluorobenzyl derivatives [R-SO2-N(PFB)2] and quantification of pharmacological acetazolamide in human urine. J Pharm Anal 2020;10:49–59.

23. Lopez M, Vu H, Wang CK, et al. Promiscuity of carbonic anhydrase II. Unexpected ester hydrolysis of carbohydrate-based sulfamate inhibitors. J Am Chem Soc 2011;133: 18452–62.

24. Di Fiore A, Supuran CT, Scaloni A, De Simone G. Human carbonic anhydrases and post-translational modifications: a hidden world possibly affecting protein properties and functions. J Enzyme Inhib Med Chem 2020;35:1450–61.

25. Bruice TC, York JL. The Mechanism of the reaction of tris-(hydroxymethyl)-aminomethane and pentaerythritol with phenyl esters. J Am Chem Soc 1961;83:1382–7.

26. Eysteinsson T, Gudmundsdottir H, Hardarson AO, et al. Carbonic anhydrase inhibitors of different structures dilate pre-contracted porcine retinal arteries. Int J Mol Sci 2019;20: 467.

27. Nielsen PM, Fago A. Inhibitory effects of nitrite on the reactions of bovine carbonic anhydrase II with CO_2 and bicarbonate consistent with zinc-bound nitrite. J Inorg Biochem 2015;149:6–11.

28. Bílková Z, Malá J, Hrich K. Fate and behaviour of veterinary sulphonamides under denitrifying conditions. Sci Total Environ 2019;695:133824.

29. Tsikas D, Ikic M, Tewes KS, et al. Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets. FEBS Lett 1999;442:162–6.

30. Gambaryan S, Tsikas D. A review and discussion of platelet nitric oxide and nitric oxide synthase: do blood platelets produce nitric oxide from L-arginine or nitrite? Amino Acids 2015;47:1779–93.

31. Jakubowski M, Szahidewicz-Krupska E, Doroszko A. The human carbonic anhydrase II in platelets: an underestimated field of its activity. Biomed Res Int 2018;2018:4548353.

32. Liang Z, Xue Y, Behravan G, et al. Importance of the conserved active-site residues Tyr7, Glu106 and Thr199 for the catalytic function of human carbonic anhydrase II. Eur J Biochem 1993;211:821–7.

33. Mikulski R, Avvaru BS, Tu C, et al. Kinetic and crystallographic studies of the role of tyrosine 7 in the active site of human carbonic anhydrase II. Arch Biochem Biophys 2011; 506:181–7.

34. Tsikas D, Sandmann J, Rossa S, et al. Investigations of S-transnitrosylation reactions between low- and high-molecular-weight S-nitroso compounds and their thiols by high-performance liquid chromatography and gas chromatography-mass spectrometry. Anal Biochem 1999;270:231–41.

35. Tsikas D, Böhmer A, Gros G, Endeward V. Evidence of the chemical reaction of (18)O-labelled nitrite with CO_2 in aqueous buffer of neutral pH and the formation of (18)OCO by isotope ratio mass spectrometry. Nitric Oxide 2016;55-56: 25–35.

36. Adamczyk K, Prémont-Schwarz M, Pines P, et al. Real-time observation of carbonic acid formation in aqueous solution. Science 2009;326:1690–4.

37. Rix PJ, Vick A, Attkins NJ, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of nebulized sodium nitrite (AIR001) following repeat-dose inhalation in healthy subjects. Clin Pharmacokinet 2015;54:261–72.

38. Sütö T, Losonczy G, Qiu C, et al. Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production. Kidney Int 1995;48:1272–7.

39. Chobanyan-Jürgens K, Schwarz A, Böhmer A, et al. Renal carbonic anhydrases are involved in the reabsorption of endogenous nitrite. Nitric Oxide 2012;26:126–31.

40. Böhmer A, Jordan J, Tsikas D. High-performance liquid chromatography ultraviolet assay for human erythrocytic catalase activity by measuring glutathione as o-phthalaldehyde derivative. Anal Biochem 2011;410:296–303.

41. Sirirat K, Sriwantana T, Kaewchuchuen J, et al. Pharmacokinetics and pharmacodynamics of single dose of inhaled nebulized sodium nitrite in healthy and hemoglobin E/β-thalassemia subjects. Nitric Oxide 2019;93:6–14.

42. Sly WS, Whyte MP, Krupin T, V, Sundaram V. Positive renal response to intravenous acetazolamide in patients with carbonic anhydrase II deficiency. Pediatr Res 1985;19:1033–6.

43. Sundaram V, Rumbolo P, Grubb J, et al. Carbonic anhydrase II deficiency: diagnosis and carrier detection using differential enzyme inhibition and inactivation. Am J Hum Genet 1986;38:125–36.

44. Xu J, Barone S, Brooks MB, Soleimani M. Double knockout of carbonic anhydrase II (CAII) and Na(+)-Cl(-) cotransporter (NCC) causes salt wasting and volume depletion. Cell Physiol Biochem 2013;32:173–83.

45. Tu C, Wynns GC, Silverman D. Inhibition by cupric ions of 18O exchange catalyzed by human carbonic anhydrase II. Relation to the interaction between carbonic anhydrase and hemoglobin. J Biol Chem 1981;256:9466–70.

46. Lindskog S, Nyman PO. Metal-binding properties of human erythrocyte carbonic anhydrases. Biochim Biophys Acta 1964;85:462–74.

47. Coleman JE. Human carbonic anhydrase. Protein conformation and metal ion binding. Biochemistry 1965;4:2644–55.

48. Tabbì G, Magrì A, Rizzarelli E. The copper(II) binding centres of carbonic anhydrase are differently affected by reductants that ensure the redox intracellular environment. J Inorg Biochem 2019;199:110759.

49. Kim JK, Lee C, Lim SW, et al. Elucidating the role of metal ions in carbonic anhydrase catalysis. Nat Commun 2020;11:4557.

50. Andring JT, Kim CU, McKenna R. Structure and mechanism of copper-carbonic anhydrase II: a nitrite reductase. IUCr 2020;7:287–93.

51. Liljas A. An enzyme in disguise. IUCrJ 2020;7:144–5.

52. Tsikas D. Comment on the article Structure and mechanism of copper-carbonic anhydrase II: a nitrite reductase. IUCrJ 2021;8 (2 pages).

53. Rózga M, Sokołowska M, Protas AM, Bal W. Human serum albumin coordinates Cu(II) at its N-terminal binding site with 1 pM affinity. J Biol Inorg Chem 2007;12:913–8.

54. Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.

55. Angeli A, Carta F, Nocentini A, et al. Response to perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors. Biophys J 2020;120:178–81.

56. Srihirun S, Schechter AN, Piknova B. Platelet-based detection of nitric oxide in blood by measuring VASP phosphorylation. J Vis Exp 2019;143:e58647.

57. Tsikas D. GC-MS approach revealing hidden nitrite reactions in hemolysate using ^{18}O-labelled nitrite and cysteine-based thiols. Anal Biochem 2021;613:114025

58. Truppo E, Supuran CT, Sandomenico A, et al. Carbonic anhydrase VII is S-glutathionylated without loss of catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem Lett 2012;22:1560–4.